Esperion Therapeutics Inc ESPR:NASDAQ

RT Quote | NASDAQ | USD
Last | 03/04/21 EST
27.46quote price arrow down-0.03 (-0.11%)
Volume
672,278
52 week range
23.90 - 56.10

...

Loading . . .

KEY STATS

  • Open27.49
  • Day High27.95
  • Day Low26.08
  • Prev Close27.46
  • 52 Week High56.10
  • 52 Week High Date03/05/20
  • 52 Week Low23.90
  • 52 Week Low Date11/03/20
  • Market Cap767.23M
  • Shares Out27.94M
  • 10 Day Average Volume0.69M
  • Dividend-
  • Dividend Yield-
  • Beta1.23
  • 1 Year % Change-50.74

RATIOS/PROFITABILITY

  • EPS (TTM)-5.48
  • P/E (TTM)-5.01
  • Fwd P/E (NTM)-2.43
  • EBITDA (MRQ)-120.849M
  • ROE (MRQ)-260.79%
  • Revenue (MRQ)227.55M
  • Gross Margin (MRQ)98.95%
  • Net Margin (MRQ)-63.09%
  • Debt To Equity (MRQ)-186.58%

EVENTS

  • Earnings Date05/04/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Esperion Therapeutics Inc News

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Esperion Therapeutics, Inc. is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company's lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol...
Timothy Mayleben
President
Sheldon Koenig
Chief Operating Officer
Richard Bartram
Chief Financial Officer
Address
3891 Ranchero Dr Ste 150
Ann Arbor, MI
48108-2837
United States